公开(公告)号：US20210393742A1

公开(公告)日：2021-12-23

申请号：US17292135

申请日：2019-11-08

申请人： Nektar Therapeutics

发明人： Takahiro Miyazaki ,  Loui Madakamutil ,  Saul Kivimae

IPC分类号： A61K38/20 ,  A61K47/54 ,  A61K39/395 ,  A61P35/00

摘要： The instant disclosure provides a combination treatment, composition and kit comprising (a) a long-acting IL-15 receptor agonist and (b) one or more antibodies (mAb) targeting a tumor antigen, related methods of preparation and use, for example, in the treatment of conditions responsive to therapy effective to provide, for example, sustained immune activation and/or anti-tumor activity.

公开(公告)号：US11744898B2

公开(公告)日：2023-09-05

申请号：US16475972

申请日：2018-01-10

申请人： Nektar Therapeutics

发明人： Zhongxu Ren ,  Neel K. Anand ,  Haiying Cai ,  Bo-Liang Deng ,  Bhalchandra V. Joshi ,  Jonathan Zalevsky ,  Takahiro Miyazaki ,  Saul Kivimae

IPC分类号： A61K47/60 ,  A61K47/54 ,  A61K47/64 ,  A61P35/00 ,  A61K9/00

CPC分类号： A61K47/60 ,  A61K9/0029 ,  A61K47/54 ,  A61K47/642 ,  A61P35/00

摘要： Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: (I) or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.

RQ-POLY-Xr-TLR7/8 AG)q  (I)

公开(公告)号：US20230158164A1

公开(公告)日：2023-05-25

申请号：US17601611

申请日：2020-04-04

申请人： Nektar Therapeutics ,  Fred Hutchinson Cancer Research Center

发明人： Antonio Mario Querido Marcondes ,  Peter Benedict Kirk ,  Takahiro Miyazaki ,  Cameron J. Turtle ,  Stanley R. Riddell ,  Cassie K. Chou ,  Simon P. Fräßle

IPC分类号： A61K47/64 ,  A61K35/17 ,  C07K16/28 ,  A61P35/00 ,  A61K9/00 ,  A61K38/17

CPC分类号： A61K47/642 ,  A61K35/17 ,  C07K16/2803 ,  A61P35/00 ,  A61K9/0019 ,  A61K38/1774 ,  C07K2317/24

摘要： Provided are methods and compositions directed to the treatment of an individual having cancer by (i) administering to the individual an adoptive cellular immunotherapy composition comprising CAR T cells and (ii) administering to the individual an interleukin-15 receptor agonist, such as, for example, a long-acting interleukin-15 receptor agonist.

公开(公告)号：US20230372500A1

公开(公告)日：2023-11-23

申请号：US18221300

申请日：2023-07-12

申请人： Nektar Therapeutics

发明人： Zhongxu Ren ,  Neel K. Anand ,  Haiying Cai ,  Bo-Liang Deng ,  Bhalchandra V. Joshi ,  Jonathan Zalevsky ,  Takahiro Miyazaki ,  Saul Kivimae

IPC分类号： A61K47/60 ,  A61K47/54 ,  A61K47/64 ,  A61P35/00 ,  A61K9/00

CPC分类号： A61K47/60 ,  A61K47/54 ,  A61K47/642 ,  A61P35/00 ,  A61K9/0029

摘要： Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I:


RQ-POLY-Xr-TLR7/8 AG)q  Formula I

or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.

公开(公告)号：US20210128737A1

公开(公告)日：2021-05-06

申请号：US16475972

申请日：2018-01-10

申请人： Nektar Therapeutics

发明人： Zhongxu Ren ,  Neel K. Anand ,  Haiying Cai ,  Bo-Liang Deng ,  Bhalchandra V. Joshi ,  Jonathan Zalevsky ,  Takahiro Miyazaki ,  Saul Kivimae

IPC分类号： A61K47/60 ,  A61P35/00 ,  A61K9/00 ,  A61K47/54 ,  A61K47/64

摘要： Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: (I) or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods. RQ-POLY-Xr-TLR7/8 AG)q   (I)